key: cord-0954510-qlwtjdmz
authors: Gambichler, T.; Hamdani, N.; Budde, H.; Sieme, M.; Skrygan, M.; Scholl, L.; Dickel, H.; Behle, B.; Ganjuur, N.; Scheel, C.; Abu Rached, N.; Ocker, L.; Stranzenbach, R.; Doerler, M.; Pfeiffer, L.; Becker, J.C.
title: Bullous pemphigoid after SARS‐CoV‐2 vaccination: Spike protein‐directed immunofluorescence confocal microscopy and T cell receptor studies
date: 2021-11-13
journal: Br J Dermatol
DOI: 10.1111/bjd.20890
sha: 5666de81c8fe4f48b47adf8789e9340c4e42164d
doc_id: 954510
cord_uid: qlwtjdmz

Dear Editor, Growing evidence suggests that SARS‐CoV‐2 vaccination is associated with a variety of cutaneous reactions, also including autoimmune‐mediated conditions such as autoimmune blistering diseases such as bullous pemphigoid (BP).(1,2) We report new‐onset BP in two patients following the first SARS‐CoV‐2 vaccination.

diseases such as bullous pemphigoid (BP). 1, 2 We report new-onset BP in two patients following the first SARS-CoV-2 vaccination.

The first patient was an 80-year-old male who noticed reddish itchy macules with small blisters on his lower legs one week after vaccination with BTN162b2. 2 Two weeks later, after he had received his second shot, these erythematous/bullous lesions spread over his trunk (Fig. 1a) . The second patient was an 89year-old male who noticed two days after the first BTN162b2 vaccination itchy erythematous/bullous lesions on his entire integument. None of the patients reported intake of any new medications or newly diagnosed other conditions prior to the AIBDs.

In both cases, sub-epidermal clefts were demonstrated on routine histology (Fig. 1b) . In both patients, . We did not observe immunoreactivity for SARS-CoV-2 spike protein in the subepidermal compartment. There was only a very likely unspecific immunoreactivity in the horny layer of patients' and controls' skin specimens (Fig. 1c, d) . High throughput sequencing of the TCRVβ CDR3 and TCR repertoire was investigated on lesional skin tissue and isolated PBMCs. Within the lesions of both patients, we observed a high clonality of T cells, with the top expanded T cell clone contributing almost 20% of all TCR transcripts (Figure 1e) . Using TCRMatch to estimate the antigen specificity of the expanded T cell clonotype we found that several of the expanded T cell clones were indeed SARS-CoV-2-reactive (Figure 1f) . Using the grouping of lymphocyte interactions by paratope hotspots algorithm, we identified several TCR clusters derived from T cells in lesional tissue as well as peripheral blood that co-clustered with the added spike protein-reactive TCRs (Figure 1g) . 3, 4 Importantly, by contrast, in control tissues obtained prior to the COVID-19 pandemic or SARS-CoV-2 vaccinations, SARS-CoV-2 spike protein reactive T cells were not observed (data not shown).

The similarities with respect to timing as well as clinical and molecular features in the cases presented here point to a causal relationship between the vaccination and BP. There are several published cases of Accepted Article vaccine-induced BP, the majority involving influenza but more recently also COVID-19. 1, 5, 6 For SARS-CoV-2 vaccines, the target antigen is the surface spike protein, which is used by the virus to bind and fuse with host cells. When speculating on autoimmune mechanisms following SARS-CoV-2 infection one may particularly consider molecular mimicry. 7, 8 We hypothesized that molecular mimicry may exist between basement membrane-specific proteins (e.g., BP-180, BP-230) and SARS-CoV-2 spike protein. However, using an antibody against spike protein we could not confirm this hypothesis. With respect to the TCR repertoire in lesional skin, we observed a marked clonal expansion of T cells in both patients with BP, indicating an ongoing adaptive immune response. We cannot exclude, however, that this T cell expansion was an epiphenomenon due to the vaccination per se. The two bioinformatic approaches further suggested that these T cell responses were reactive to SARS-CoV-2 derived epitopes. 3, 4 Our TCRMatch results suggested that some of the expanded T cell clones detected in the patients might be reactive to other SARS-CoV-2 derived epitopes including nucleocapsid proteins. However, whether these T cell clones might hint to an undocumented previous infection with SARS-CoV2 or some other mechanism, whereby a spike protein-vaccine may induce such T cells, remains unclear at this point.

Bullous pemphigoid and COVID-19 vaccine

Cutaneous findings following COVID-19 vaccination: Review of world literature and own experience

TCRMatch: Predicting T-Cell Receptor Specificity Based on Sequence Similarity to Previously Characterized Receptors. Front Immunol

Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening

Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger